Compartilhar
Informação da revista
Compartilhar
Compartilhar
Baixar PDF
Mais opções do artigo
Letter - Therapy
Acesso de texto completo
Disponível online em 21 de outubro de 2024
Surgical avulsion of the nail plate as therapy for resistant onychomycosis: case series and literature review
Visitas
228
José Antônio Jabur da Cunhaa, Fernanda Santana Barbosaa, Gustavo de Sá Menezes Carvalhoa,
Autor para correspondência
gustavo.carvalho@msn.com

Corresponding author.
, John Verrinder Veaseya,b
a Dermatology Clinic, Hospital da Santa Casa de São Paulo, São Paulo, SP, Brazil
b Discipline of Dermatology, Faculdade de Ciências Médicas, Santa Casa de São Paulo, São Paulo, SP, Brazil
Este item recebeu
Recebido 14 Abril 2024. Aceite 03 Junho 2024
Informação do artigo
Texto Completo
Bibliografia
Baixar PDF
Estatísticas
Figuras (1)
Tabelas (3)
Table 1. Clinical personal history of patients with refractory onychomycosis undergoing nail plate avulsion: gender, age and comorbidities.
Table 2. Characteristics of onychomycoses treated by nail avulsion: affected digit, results of mycological examinations and treatments performed prior to the procedure.
Table 3. Evolution of patients after avulsion of the affected nail plate.
Mostrar maisMostrar menos
Texto Completo
Dear Editor,

Onychomycosis is a fungal infection of the nails caused by dermatophytes, non-dermatophytic filamentous fungi (NDFF), and yeasts, and is the most commonly observed nail disease in clinical practice.1,2 Although common, treatment can be challenging, given the rise in reported resistant cases, either due to an increase in the number of cases related to NDFF that have recognized resistance to classical treatment,1,2 or due to virulence factors related to pathogens such as biofilm production, or due to the host's immunological inability to defend himself.3,4

Contrary to what was previously thought, the fungi involved in onychomycosis are capable of alternating between the planktonic form and the biofilm presentations.4 The term planktonic refers to isolated fungal cells, freely suspended in a medium, whereas in the form of biofilms, these cells adhere to a surface and form extensive collaborative multicellular communities surrounded by an extracellular matrix.4,5 In fact, despite being recognized as susceptible to antifungal drugs, the reasons why onychomycosis tends to be refractory to treatments are still uncertain, with a possible relationship with the microenvironment of the nail apparatus and the formation of biofilms suggested as possibilities.5

Ideally, biofilms should be removed before starting drug treatment, implying the need for combination therapies.5 Procedures such as onychoabrasion, laser, photodynamic therapy, chemical or surgical avulsion are some of the techniques suggested for removing/rupturing the biofilm, thus facilitating drug action.4,6

A retrospective study was conducted, analyzing patients treated at the Dermatology Clinic between January 2016 and December 2023 with onychomycosis refractory to classical drug treatment, who underwent surgical avulsion as alternative therapy. Cases with clinical and onychoscopic suspicion of onychomycosis, and with direct mycological examination (DME) and fungal culture positive were included. The combination of oral antifungals (terbinafine and/or itraconazole) with topical antifungals in nail polish formulation (ciclopirox olamine 5% or amorolfine 8%) was considered as the classical treatment and those who did not show any clinical improvement after one year of pharmacological treatment were considered to be resistant.

Eight patients with 12 treated nails were included in the study (Table 1). All had DME with evidence of fungi; the etiological agent was isolated as NDFF in nine cases, Neoscytalydium dimidiatum var. hyalinum in six, Fusarium sp in three, in addition to one with Trichophyton rubrum and another with Candida sp. (Table 2). Regarding nail surgery, in eight cases it was performed via the proximal approach of the nail plate and in the other four via the distal approach. The distal technique was indicated for patients with evident onycholysis where nail detachment can be performed in a less traumatic manner. None of the patients developed complications in the postoperative period and all had nail plate growth after the procedure (Table 3). Because this is a procedure with low morbidity (with the use of local anesthesia) and short surgical time, none of the patients were excluded from the study.

Table 1.

Clinical personal history of patients with refractory onychomycosis undergoing nail plate avulsion: gender, age and comorbidities.

Identification
Number  Gender  Age  Comorbidities 
Male  69  SAH, DLP 
Male  69  SAH, DLP 
Male  69  SAH, DLP 
Female  37  None 
Female  59  Hypothyroidism, fibromyalgia, osteoporosis 
Male  58  SAH 
Male  58  SAH 
Female  67  SAH, iS, MCTD, panic syndrome 
Female  44  None 
10  Female  57  None 
11  Female  57  None 
12  Female  26  None 

SAH, systemic arterial hypertension; DLP, dyslipidemia, iS, ischemic stroke; MCTD, mixed connective tissue disease.

Table 2.

Characteristics of onychomycoses treated by nail avulsion: affected digit, results of mycological examinations and treatments performed prior to the procedure.

Identification  Preoperative
Number  Affected digit  Direct Mycological Examination  Culture  Previous drug treatment 
1 LT  Hyaline septate hyphae  Neoscytalydium dimidiatum var hyallinuma  ITRA (200mg pulse) × TERB (500mg pulse) + amorolfine nail polish (2×/week) 
3 LT  Hyaline septate hyphae  Neoscytalydium dimidiatum var hyallinuma  ITRA (200mg pulse) × TERB (500mg pulse) + amorolfine nail polish (2×/week) 
4 LT  Hyaline septate hyphae  Neoscytalydium dimidiatum var hyallinuma  ITRA (200mg pulse) × TERB (500mg pulse) + amorolfine nail polish (2×/week) 
1 RT  Hyaline septate hyphae  Trichophyton rubrum  TERB (500mg) 
1 RT  Hyaline septate hyphae  Neoscytalydium dimidiatum var hyallinuma  ITRA (200mg pulse) × TERB (5mg pulse) + amorolfine nail polish (2×/week) 
1 RT  Hyaline septate hyphae  Fusarium sp.a  TERB (5mg pulse) + micolamina nail polish (2×/week) 
1 LT  Hyaline septate hyphae  Fusarium sp.a  TERB (500mg pulse) + micolamina nail polish (2×/week) 
1 LT  Hyaline septate hyphae  Candida sp.  TERB (250mg/d) 
3 RF  Hyaline septate hyphae  Fusarium sp.a  ITRA (200mg pulse) × TERB (500mg pulse) + amorolfine nail polish (2×/week) 
10  1 LT  Dematiaceous septate hyphae  Neoscytalydium dimidiatum var hyallinuma  ITRA (200mg pulse) × TERB (500mg pulse) + amorolfine nail polish (3×/week) 
11  1 RT  Dematiaceous septate hyphae  Neoscytalydium dimidiatum var hyallinuma  ITRA (200mg pulse) × TERB (500mg pulse) + amorolfine nail polish (3×/week) 
12  1 RT  Hyaline septate hyphae  Fusarium sp.a  ITRA (200mg pulse) × TERB (500mg pulse) + amorolfine nail polish (3×/week) 

LT, left toe; RT, right toe; RF, right finger; ITRA, itraconazole; TERB, terbinafine.

a

Agent isolated in at least three samples with an interval of at least two weeks between them, without isolation of any other pathogen.

Table 3.

Evolution of patients after avulsion of the affected nail plate.

Identification  Surgical techniquePostoperative
Number  Complication  Time of follow-up  Treatment  Evolution 
Proximal  None  26 months  Micolamina nail polish 1 ×/w for 20 months  Healthy nail growth 
Proximal  None  13 months  Micolamina nail polish 1×/w for 7 months  Healthy nail growth 
Proximal  None  13 months  Micolamina nail polish 1×/w for 7 months  Healthy nail growth 
Distal  None  15 months  TERB (500mg pulse) + Butenafine cream 1×/d for 4 months  Healthy nail growth 
Proximal  None  39 months  Micolamina nail polish 1×/w for 5 months  Dystrophic nail growth 
Distal  None  31 months  TERB (500mg pulse) isoconazole cream 1×/d+micolamina nail polish 1×/w for 15 months  Dystrophic nail growth 
Proximal  None  28 months  TERB (500mg pulse) + Butenafine cream 1×/d for 12 months  Dystrophic nail growth 
Proximal  None  2 months  None  Healthy nail growth 
Proximal  None  75 months  None  Healthy nail growth 
10  Distal  None  62 months  TERB (500mg pulse) + Tefin cream 1×/d for 5 months  Healthy nail growth 
11  Distal  None  62 months  TERB (500mg pulse) + Tefin cream 1×/d for 5 months  Healthy nail growth 
12  Proximal  None  6 months  ITRA (200mg pulse) + TERB (500mg pulse) + micolamina nail polish 1×/w for 6 months  Healthy nail growth 

TERB, terbinafine; ITRA, itraconazole; d, day; w, week.

Two surgical techniques were used: proximal total nail avulsion and distal total nail avulsion. Proximal digital blockade was used because the authors believe it is efficient and not very painful, with 2% xylocaine as a vasoconstrictor. After the digit was completely anesthetized, a tourniquet was applied. In the proximal technique, the nail plate is completely detached from the proximal nail fold using a nail remover tool, supporting the remover tool on the nail plate so as not to lose the correct plane. Once completely detached, the proximal portion of the nail is pulled above the proximal nail fold using a lever. This movement begins in the central portion of the nail and then extends to the lateral horns. Once the entire proximal portion of the nail plate has been retracted, it is gently detached from proximal to distal. In the distal technique, the nail plate is detached globally at all its connections with the nail folds, from distal to proximal, using a nail remover tool, and then the nail is removed. This technique tends to be more traumatic and it is not very useful when there is severe onychodystrophy.

After surgery, classic topical and oral antifungal treatment was maintained in all patients until the nail plate had grown back completely. The nine nails showed growth of the new plate without signs of infection during the follow-up period (Fig. 1). Three cases showed growth of the nail plate with dystrophy. After the avulsion only clinical signs were observed and no laboratory tests (DME or culture for fungi) were performed. The choice of using medication after the avulsion of the plate aimed at reducing pathogens in the nail apparatus (matrix, bed, folds) which could be a reservoir for recontamination, just as tinea pedis is in patients with recurrent onychomycosis.1 Several studies propose a combination of biofilm-targeted therapies and conventional drug treatments to increase the success rate in the treatment of refractory onychomycosis.4,6,7 Avulsion is a valid choice in this scenario, and according to the experience of the who conducted the study has a satisfactory cure rate.

Fig. 1.

(A) Onychomycosis affecting the right hallux due to Fusarium sp. refractory to pharmacological treatment. (B) After six months of nail avulsion, followed by treatment with itraconazole (200mg pulse), terbinafine (500mg pulse) and micolamina nail polish.

(0.14MB).

Analyzing the cases in which the nail plate presented dystrophy after surgical avulsion, it is suggested that the condition may not be solely of infectious origin but may be associated with other factors such as nail trauma caused by patients walking habits.6–8 Given the considerable number of isolated NDFF, it is also possible to consider the hypothesis that these pathogens would not be the sole cause of the nail alteration, but rather secondary agents of onychomycotization. In these cases, it would be necessary to combine other therapeutic and behavioral measures in addition to fighting the infectious process to achieve complete improvement of the condition.1,4,6 It is important to emphasize that no patient developed an unfavorable condition after the procedure: in the worst scenario, the nail persisted with the previously observed dystrophy, with no case developing bleeding, infection, or pain.

The study data are promising and open perspectives for more robust studies, so it is important to discuss, at this time, avulsion as an alternative option for refractory cases, in association with systemic treatment. However, the study has limitations that need to be clarified: the small number of patients, lack of uniformity in the postoperative treatment, the fact that it is a retrospective study and no DME or culture was performed on the nails after the end of the treatment, especially in cases with dystrophy, which makes it difficult to prove the cure; in addition, there was no long-term follow-up, which hinders the assessment of therapeutic failure.

Financial support

None declared.

Authors' contributions

José Antônio Jabur da Cunha: Design and planning of the study; data collection, or analysis and interpretation of data; drafting and editing of the manuscript or critical review of important intellectual content; collection, analysis and interpretation of data; intellectual participation in the propaedeutic and/or therapeutic conduct of the studied cases; critical review of the literature; approval of the final version of the manuscript.

Fernanda Santana Barbosa: Data collection, or analysis and interpretation of data; statistical analysis; collection, analysis and interpretation of data; critical review of the literature.

Gustavo de Sá Menezes Carvalho: Data collection, or analysis and interpretation of data; statistical analysis; collection, analysis and interpretation of data; critical review of the literature.

John Verrinder Veasey: Design and planning of the study; data collection, or analysis and interpretation of data; drafting and editing of the manuscript or critical review of important intellectual content; collection, analysis and interpretation of data; intellectual participation in the propaedeutic and/or therapeutic conduct of the studied cases; critical review of the literature; approval of the final version of the manuscript.

References
[1]
S.R. Lipner, R.K. Scher.
Onychomycosis: clinical overview and diagnosis.
J Am Acad Dermatol., 80 (2019), pp. 835-851
[2]
J.V. Veasey, F. Nappi, C. Zaitz, L.H. Muramatu.
Descriptive analysis of mycological examination of patients with onychomycosis treated in private practice.
An Bras Dermatol., 92 (2017), pp. 134-136
[3]
G.A. Celestrino, J. Verrinder Veasey, G. Benard, M.G.T. Sousa.
Host immune responses in dermatophytes infection.
Mycoses., 64 (2021), pp. 477-483
[4]
A.K. Gupta, D. Daigle, J.L. Carviel.
The role of biofilms in onychomycosis.
J Am Acad Dermatol., 74 (2016), pp. 1241-1246
[5]
A.K. Gupta, J. Carviel, N.H. Shear.
Antibiofilm treatment for onychomycosis and chronic fungal infections.
Skin Appendage Disord., 4 (2018), pp. 136-140
[6]
C. Grover, S. Bansal, S. Nanda, B.S. Reddy, V. Kumar.
Combination of surgical avulsion and topical therapy for single nail onychomycosis: a randomized controlled trial.
Br J Dermatol., 157 (2007), pp. 364-368
[7]
D. Pandhi, P. Verma.
Nail avulsion: indications and methods (surgical nail avulsion).
Indian J Dermatol Venereol Leprol., 78 (2012), pp. 299-308
[8]
W.Y. Lai, W.Y. Tang, S.K. Loo, Y. Chan.
Clinical characteristics and treatment outcomes of patients undergoing nail avulsion surgery for dystrophic nails.
Hong Kong Med J., 17 (2011), pp. 127-131

Study conducted at the Dermatology Clinic, Hospital da Santa Casa de São Paulo, São Paulo, SP, Brazil.

Copyright © 2024. Sociedade Brasileira de Dermatologia
Baixar PDF
Idiomas
Anais Brasileiros de Dermatologia (Portuguese)
Opções de artigo
Ferramentas
en pt
Cookies policy Política de cookies
To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.